Immunoglobulin A nephropathy: Fish oils and beyond

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 5, 1996, Pages 442-446

  Feehally, John ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; FISH OIL;

HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; PRIORITY JOURNAL; REVIEW;

EID: 0029985048     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199609000-00011     Document Type: Review

References (27)

1. Galla JH: IgA nephropathy. Kidney Int 1995, 47:377-387. This is a succinct up-to-date summary of IgA nephropathy from a clinician's standpoint. It gives a balanced account of the epidemiology, pathophysiology, clinical features, prognosis and treatment.
2. Ibels LS, Gyory AZ: IgA nephropathy: analysis of the natural history, Important factors In the progression of renal disease and a review of the literature. Medicine 1994, 73:79-102.
3. Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S, Holland NH, Jackson E, Bishof NA: IgA nephropathy: long-term prognosis for pédiatrie patients. J Pediatr 1995, 127:913-919.
4. Allen AC: Abnormal glycosylation of IgA; is it related to the pathogenesis of IgA nephropathy? Nephrol Dial Transplant 1995, 10:1121-1124. The present knowledge of abnormal IgA glycosylation in IgA nephropathy is reviewed with speculation on its role in pathogenesis. These insights may eventually lead to a more fundamental approach to the treatment of IgA nephropathy by directly reducing IgA deposition.
5. Niemer ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R: PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995, 48:1530-1541.
6. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995, 96:2162-2169. Strong evidence is given for the influence of the ACE gene deletion polymorphism DD on progression risk in Japanese with IgA nephropathy. An open study of ACE inhibitors also suggests that the DD genotype influences the response of proteinuria to ACE inhibitors.
7. Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M: Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 1995, 44:80-85.
8. Fukushima T, Nomura S, Kawai S, Osawa G: ACE genotype and progression of IgA nephropathy [Letter]. Lancet 1995; 346:571.
9. Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campsie M, Mayer G et al.: No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995, 26:727-731. It was found that, even in a large group of Caucasians (n=204) with IgA nephropathy, the association of the DD ACE genotype with risk of progression could not be confirmed.
10. Harden P, Gedde C, Rowe P, McIlroy J, Boulton-Jones M, Rodger R, Junor B, Briggs J, Connell J, Jardine A: Polymorphisms in angiotensin-converting enzyme gene and progression of IgA nephropathy. Lancet 1995, 345:1540-1542.
11. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong P: Association between angiotensin-converting enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996, 347:94-95. The DD ACE genotype is reported to mark the risk of progression in a range of chronic renal disease, not only IgA nephropathy. The response of proteinuria to ACE inhibitors was not associated with DD in this study.
12. Rekola S, Bergstrand A, Bucht H: Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 1991, 57:57-60.
13. Cattran D, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994, 23:247-254.
14. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccala A, Zucchelli P: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomised, placebo-controlled trial. Nephrol Dial Transplant 1994, 9:265-269.
15. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995, 111:184-193. This is the only prospective randomized study of ACE inhibitor versus calcium antagonist in IgA nephropathy. It is a small study with only 12 months follow-up, but no difference in renal function was found, even though proteinuria was reduced further by ACE inhibitor.
16. Bennett WM, Walker RG, Kincaid-Smith: Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol 1989, 31:128-131.
17. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Bjorkhelm I, Bergstrom J: Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomised study. Clin Nephrol 1994, 41:183-190.
18. Donadio JV, Bergstalh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994, 331:1194-1199.
19. Feehally J: Strategies for the management of IgA nephropathy. In Annual yearbook of nephrology, dialysis, and transplantation. Oxford: Oxford University Press; 1994:23-29.
20. Hogg RJ: A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with IgA nephropathy. Am J Kidney Dis 1995, 26:792-796.
21. Goumenos D, Ahuja M, Shortland JR, Brown CB: Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant 1995, 10:1173-1181.
22. Woo KT, Edmondson RPS, Yap HK, Wu AYT, Chiang GSC, Lee EJC, Pwee HS, Lim CH: Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1989, 27:56-64.
23. Walker RG, Yu SH, Owen JE, Kincaid-Smith P: The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two year prospective trial. Clin Nephrol 1990, 34:103-107.
24. Ballardie FW, Roberts IDS: A controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [Abstract]. Nephrol Dial Transplat 1996 (in press).
25. Berkman S, Lee ML, Gale RP: Clinical uses of intravenous immunoglobulin. Ann Intern Med 1990, 112:278-292.
26. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S et al.: High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 1994, 120:476-484.
27. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S et al.: Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995, 69:327-334.